Eli Lilly fleshes out more PhIII data for Dupixent challenger as AD rivalry heats up
Eli Lilly outlined more data for its IL-13 inhibitor Monday as it prepares to challenge the megablockbuster Dupixent in atopic dermatitis.
Lilly’s lebrikizumab cleared up patients’ skin at a statistically significantly greater rate compared to placebo in two different measurements, the pharma said Monday morning, fleshing out the pivotal trial data package ahead of an eventual NDA submission. Monday’s readout was lebrikizumab’s third Phase III study to read out positively.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.